Despite Focus on Generics, South Korean Pharma Expected to Achieve $24.3 Billion Value by 2020
South Korean pharmaceutical industry value to grow from $19.3 billion in 2013 to $24.3 billion by 2020
According to global research firm, Global Data, the South Korean pharmaceutical industry's value will grow from $19.3 billion in 2013 to $24.3 billion by 2020, at a Compound Annual Growth Rate of 3.9%. Growth analysts attribute to a high level of access to healtcare insurance and reimbursement, in addition to the demand for healthcare by the aging population.
Projects aimed at R&D, and government initiatives to support the Korean Small Business Innovation Research Program, are also attributed to the growth, according to the company’s latest report*.
Joshua Owide, Director of Healthcare Industry Dynamics at GlobalData adds, “Additionally, since signing the Free Trade Agreement with the US in 2007, South Korea has lowered its import tariffs, enhanced its regulatory transparency, and attracted investment from multinational pharmaceutical companies.”
South Korea will maintain its focus on generics as a cost-containment measure to slow the rise of its healthcare expenditure—the country’s generic market value has increased from $3.5 billion in 2008 to an estimated $4.9 billion in 2013, at a CAGR of 7%—at the cost of branded-drug profits.
*CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - South Korea
Read the full release here.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
